Get started
Author

Akifumi Omiya

ORCID: 0009-0009-1397-9792
Observed ORCID: 0009-0009-1397-9792
OpenAlex ID: A5111247404
Prognostic Impact of Immune-Related Adverse Events on Combination Immune Checkpoint/Tyrosine Kinase Inhibition for Metastatic Renal Cancer
2025 · Bunpei Isoda, Masanobu Shiga, et al. · Cancer Research Communications · 1
PDF
Combination Chemotherapy With TS-1 and Cisplatin for Urinary Adenocarcinoma: A Retrospective Case Series
2024 · Akifumi Omiya, Satoshi Nitta, et al. · Clinical Genitourinary Cancer · 1
PDF
Assessment of Multiple Prognostic Scores in Patients With Metastatic Renal Cell Carcinoma Receiving First‐Line, Immune‐Based Combinations
2026 · Hiromichi Sakurai, Masanobu Shiga, et al. · Cancer Reports
Table 1 from Prognostic Impact of Immune-Related Adverse Events on Combination Immune Checkpoint/Tyrosine Kinase Inhibition for Metastatic Renal Cancer
2025 · Bunpei Isoda, Masanobu Shiga, et al.
Supplemental Table 1 from Prognostic Impact of Immune-Related Adverse Events on Combination Immune Checkpoint/Tyrosine Kinase Inhibition for Metastatic Renal Cancer
2025 · Bunpei Isoda, Masanobu Shiga, et al.
Data from Prognostic Impact of Immune-Related Adverse Events on Combination Immune Checkpoint/Tyrosine Kinase Inhibition for Metastatic Renal Cancer
2025 · Bunpei Isoda, Masanobu Shiga, et al.
Table 4 from Prognostic Impact of Immune-Related Adverse Events on Combination Immune Checkpoint/Tyrosine Kinase Inhibition for Metastatic Renal Cancer
2025 · Bunpei Isoda, Masanobu Shiga, et al.
Figure 2 from Prognostic Impact of Immune-Related Adverse Events on Combination Immune Checkpoint/Tyrosine Kinase Inhibition for Metastatic Renal Cancer
2025 · Bunpei Isoda, Masanobu Shiga, et al.
Figure 1 from Prognostic Impact of Immune-Related Adverse Events on Combination Immune Checkpoint/Tyrosine Kinase Inhibition for Metastatic Renal Cancer
2025 · Bunpei Isoda, Masanobu Shiga, et al.
Figure 3 from Prognostic Impact of Immune-Related Adverse Events on Combination Immune Checkpoint/Tyrosine Kinase Inhibition for Metastatic Renal Cancer
2025 · Bunpei Isoda, Masanobu Shiga, et al.
Table 3 from Prognostic Impact of Immune-Related Adverse Events on Combination Immune Checkpoint/Tyrosine Kinase Inhibition for Metastatic Renal Cancer
2025 · Bunpei Isoda, Masanobu Shiga, et al.
Table 2 from Prognostic Impact of Immune-Related Adverse Events on Combination Immune Checkpoint/Tyrosine Kinase Inhibition for Metastatic Renal Cancer
2025 · Bunpei Isoda, Masanobu Shiga, et al.
Works count: 12
Citation count: 2
H-index: 1
I10-index:
Year
Topic
Type